Phase II study of 4'epi-doxorubicin

Area of Science:

• Oncology
• Pharmacology
• Cardiology

Background:

• Doxorubicin (DXR) is a widely used chemotherapy agent.
• New analogues are sought to improve efficacy and safety profiles.
• 4'epi-doxorubicin is a novel analogue of doxorubicin.

Purpose of the Study:

• To evaluate the efficacy and toxicity of 4'epi-doxorubicin in patients with advanced solid tumors.
• To compare the toxicity profile with that of doxorubicin.
• To assess the potential for a broader spectrum of activity compared to doxorubicin.

Main Methods:

• Sixty-five patients with advanced solid tumors were enrolled.
• Treatment involved 4'epi-doxorubicin at 75 mg/m2 every 21 days.
• Toxicity, including electrocardiographic changes (PEP/LVET ratio), and tumor response were monitored.

Main Results:

• Acute toxicity was similar to doxorubicin.
• Transient electrocardiographic abnormalities (PEP/LVET changes) occurred in ~50% of patients, returning to baseline within 24 hours.
• Partial responses were observed in various tumor types, including those typically sensitive and resistant to doxorubicin.

Conclusions:

• 4'epi-doxorubicin demonstrates manageable toxicity, comparable to doxorubicin.
• The drug shows promising activity across a range of solid tumors.
• 4'epi-doxorubicin may possess a broader antitumor spectrum than doxorubicin.